Wedbush reiterated their outperform rating on shares of Oculis (NASDAQ:OCS – Free Report) in a report issued on Friday morning, Benzinga reports. They currently have a $29.00 price objective on the stock. Other equities research analysts have also issued research reports about the stock. Robert W. Baird upped their price objective on shares of Oculis […]
Related Keywords
United States , America , Stifel Nicolaus , Robertw Baird , Nan Fung Group Holdings Ltd , Wolverine Asset Management , Oculis Holding , Barclays Plc , Free Report , Get Free Report , Asset Management , Oculis Daily , Oculis , Nasdaq Ocs , Docs , Medical , Reiterated Rating , Wedbush ,
comparemela.com © 2020. All Rights Reserved.